Phosphate binders and management of hyperphosphataemia in end-stage renal disease

Nephrol Dial Transplant. 2006 Aug;21(8):2065-8. doi: 10.1093/ndt/gfl289. Epub 2006 Jun 9.
No abstract available

Publication types

  • Editorial
  • Review

MeSH terms

  • Acetates / therapeutic use
  • Aluminum Compounds / adverse effects
  • Aluminum Compounds / pharmacokinetics
  • Aluminum Compounds / therapeutic use
  • Bone Diseases, Metabolic / chemically induced
  • Bone Diseases, Metabolic / prevention & control
  • Calcinosis / etiology
  • Calcinosis / prevention & control
  • Calcium Carbonate / adverse effects
  • Calcium Carbonate / therapeutic use
  • Calcium Compounds / therapeutic use
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control
  • Central Nervous System Diseases / chemically induced
  • Central Nervous System Diseases / prevention & control
  • Chronic Kidney Disease-Mineral and Bone Disorder / etiology
  • Chronic Kidney Disease-Mineral and Bone Disorder / prevention & control
  • Diet, Protein-Restricted
  • Ferric Compounds / therapeutic use
  • Humans
  • Hyperparathyroidism, Secondary / etiology
  • Hyperparathyroidism, Secondary / prevention & control
  • Kidney Failure, Chronic / blood*
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / diet therapy
  • Kidney Failure, Chronic / therapy
  • Lanthanum / pharmacokinetics
  • Lanthanum / therapeutic use*
  • Phosphates / blood*
  • Phosphorus, Dietary / administration & dosage
  • Phosphorus, Dietary / adverse effects
  • Phosphorus, Dietary / pharmacokinetics
  • Polyamines / pharmacokinetics
  • Polyamines / therapeutic use*
  • Renal Dialysis
  • Sevelamer

Substances

  • Acetates
  • Aluminum Compounds
  • Calcium Compounds
  • Ferric Compounds
  • Phosphates
  • Phosphorus, Dietary
  • Polyamines
  • ferric hydroxide
  • lanthanum carbonate
  • Lanthanum
  • Sevelamer
  • Calcium Carbonate
  • calcium acetate